These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1165 related items for PubMed ID: 26306956

  • 1. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 2. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
    Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.
    J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
    [Abstract] [Full Text] [Related]

  • 3. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [Abstract] [Full Text] [Related]

  • 4. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A, Giæver J, Granroth B, Hylander B, Jensen G, Christensson A, Wikström B, Weiss L, Wrege U, Jacobson SH.
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [Abstract] [Full Text] [Related]

  • 5. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L.
    Ren Fail; 2012 Jun; 34(3):297-303. PubMed ID: 22251408
    [Abstract] [Full Text] [Related]

  • 7. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F, Chen X, Wang C, Zhou A, Liu H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct 28; 42(10):1169-1173. PubMed ID: 29093248
    [Abstract] [Full Text] [Related]

  • 8. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F, Yudd M.
    Am J Kidney Dis; 2001 Nov 28; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [Abstract] [Full Text] [Related]

  • 9. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun 28; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers.
    Žilinská Z, Dedinská I, Breza J, Laca L.
    Iran J Kidney Dis; 2017 Nov 28; 11(6):461-466. PubMed ID: 29190607
    [Abstract] [Full Text] [Related]

  • 13. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J, Tran NT, Schomberg J, Streja E, Kalantar-Zadeh K, Pahl M.
    J Ren Nutr; 2016 Jul 28; 26(4):265-9. PubMed ID: 27038806
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
    Schwarz A, Merkel S, Leitolf H, Haller H.
    Transplantation; 2011 Mar 15; 91(5):560-5. PubMed ID: 21192318
    [Abstract] [Full Text] [Related]

  • 16. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
    Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP.
    Nephrol Dial Transplant; 2007 Feb 15; 22(2):577-83. PubMed ID: 17005527
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, Cozzolino M, FARO Study Group.
    J Med Econ; 2012 Feb 15; 15(6):1110-7. PubMed ID: 22702445
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Feb 15; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.